High expression of these genes in 316 ER+/HER2- breast cancer patients who had undergone neoadjuvant chemotherapy was not associated with a decreased relapse-free survival in the KM Plotter cohort (Figures 2G, H). Here, ERBB2 is linked to breast carcinoma.